Overview

Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This study is conducted in Asia. The aim of this observational study is to evaluate the efficacy on blood glucose control while using NovoMix® 30 FlexPen® under normal clinical practice conditions in Korea. A clinical safety profile will be also evaluated.
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Biphasic Insulins
Insulin
Insulin Aspart
Insulin aspart, insulin aspart protamine drug combination 30:70
Insulin, Isophane